|
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Clinical research trials and Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas. Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas clinical trial. Human subjects often obtain the finest healthcare possible for their Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas  Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
For Condition: Pancreatic Cancer,Gallbladder Cancer,Bile Duct Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas. PURPOSE: Phase II trial to determine the effectiveness of photodynamic therapy in treating patients who have cancer of the bile duct, gallbladder, or pancreas.
Details: OBJECTIVES: I. Determine the safety and efficacy of photodynamic therapy using porfimer sodium in patients with unresectable malignant bile duct obstruction. PROTOCOL OUTLINE: Patients are stratified according to tumor location (proximal vs distal). Patients receive porfimer sodium IV over 3-5 minutes on day 1, followed by percutaneous or endoscopic laser light treatment on day 3. Patients achieving partial response or complete response accompanied by an increase in total bilirubin or cholangitis may repeat treatment for a maximum of 3 courses. Patients are followed weekly for 1 month, and then monthly for 1 year. PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven malignant bile duct obstruction with obstructive jaundice; Primary carcinoma of bile duct, gallbladder, or pancreas OR Metastatic bile duct disease; Successful insertion of a percutaneous drain or endoscopic stent; Unresectable disease OR Resectable disease but refusal of surgery - Prior biliary plastic or metallic stent allowed, if requiring stent replacement due to recurrent jaundice or routine plastic stent change - No erosion of biliary tumors into major blood vessels - No evidence of bile duct perforation --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: At least 4 weeks since prior chemotherapy - Endocrine therapy: Not specified - Radiotherapy: No concurrent radiotherapy or brachytherapy to the abdomen - Surgery: See Disease Characteristics - Other: No other prior or concurrent experimental or investigational drugs --Patient Characteristics-- - Age: 18 and over - Performance status: Karnofsky 50-100% - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Bilirubin at least 2 mg/dL - Renal: Not specified - Other: No history of allergies or hypersensitivity to porphyrins; No porphyria; No cholangitis or pancreatitis
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HansGerdes, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000067110; MSKCC-99015,NCI-G99-1525
Study Start Date: March 1999
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003923
Other Gallbladder Cancer Studies:
1. Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
2. LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
3. Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
4. OSI-774 (Tarceva) Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
5. LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer
Related Studies:
Other Gallbladder Cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
|
|
|
|
|
|
|
|
